- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01987934
Comparison of Morphometric Assessment Using Methyl Green Pyronin and AgNOR Staining of Oral Squamous Cell Carcinoma (OSCC)
Oral cancer represents the sixth most common cancer worldwide whilst in Pakistan it ranks the second most common cancer in either gender. Histologically, over 90% of oral cancer lesions are squamous cell carcinomas which are diagnosed on the basis of histopathological analysis. However, proliferation kinetics and nucleolar status are not clearly delineated by routine H&E examination; thus making use of various proliferation markers imperative for the purpose.
Nuclear organizer regions (AgNORs) are associated with proliferative activity and represents as a diagnostic aid in oral malignancies. Similarly, methyl green pyronin (MGP) stain has also been valuable as a complement in routine histopathological studies of several neoplastic entities.
Morphometric techniques offer an opportunity to quantify nuclear changes associated with malignancy and may provide an objective basis for grading the tumors. The present study is planned to analyze the morphometric parameters of the MGP stain in oral squamous cell carcinoma, and in their various histological grades, and to assess if the MGP staining parameters could give information on the aggressiveness of the malignant lesions of oral cavity.
Sections from thirty cases of squamous cell carcinoma along with thirty cases of normal oral mucosa will be evaluated for methyl green pyronin (MGP) and AgNOR staining. Morphometric analysis of various MGP staining and AgNOR parameters would be performed using micrometer. Statistical analysis of the results will be carried out using SPSS. Quantitative variables will be expressed as mean ± Standard Deviation. Frequencies and percentages will be given for qualitative variables.
It is hypothesized that oral squamous cell carcinoma will exhibit significantly higher MGP staining and AgNOR staining parameters than normal mucosa of the oral cavity.
Study Overview
Status
Detailed Description
Oral cancer, a major global health problem holds the sixth position worldwide with a marked variation in its geographic distribution. It is ranked as the third most frequent cancer in the developing world after stomach and cervical cancers. Amongst oral cancers, oral squamous cell carcinoma accounts for over 90% of the cases.
Out of the developing counties, Indo-Pak subcontinent amounts to one third of the global oral cancer burden. Carcinoma of the oral cavity in Pakistan, one of the high-risk countries is the second most frequent cancer in either gender. With differential distribution among sub-populations, it represents 8.8% of all reported cancer cases. The most predominant risk factors include tobacco smoking, betel chewing and alcohol.
Screening and specific diagnostic tools are two innovative approaches for early detection of oral cancer. Conventional oral examination and clinical evaluation remains the foundation of screening approaches whereas surgical biopsy followed by histological analysis is attributed to be the gold standard for diagnosing malignant oral lesions. Furthermore, some adjunctive techniques may contribute to the diagnosis of oral cancer. Of these vital staining, DNA analysis, chemiluminescence, tissue fluorescence, light-based detection systems and biomarkers are now on the forefront.
Biomarkers have been valuable in revealing additional information about tumor pathology, including the inactivation of tumor suppressor genes, angiogenesis, apoptosis and cell proliferation. Aberrations in proliferation kinetics are the most imperative factor during tumor progression. Three main categories of cell proliferation markers include growth fraction markers like Ki67, cycle-specific markers like PCNA(Proliferating Cellular Nuclear Antigen), and cell cycle time markers like AgNOR. During malignancy, proliferation and protein synthesis is mainly controlled by the nucleus.
Nucleolar Organizer Regions (NORs) are loops of DNA on the short arms of acrocentric chromosomes that presumably are associated with cell proliferation. Some of the NOR associated proteins are argyrophilic and can be demonstrated as black dots by the silver staining technique and the structures thus demonstrated are known as AgNORs. The AgNOR quantitative parameters provide information about the velocity of cell proliferation during cell cycle. Neoplastic progression is affected more by the rate of cell proliferation, rather than the proliferative activity per se.
Although AgNOR staining and AgNOR quantification are valuable methods in histopathological evaluation of malignancies, certain limitations have also been associated with this technique. Such AgNOR associated shortcomings include nucleolar affinity for silver stain obscuring the individual AgNORs in cases of intense staining, overlapping of variable degree between high and low grade tumors, difficulty in discerning doublets or clusters by light microscopy, misinterpreted stain deposition as proliferative activity along with some technical problems of staining and fixation.
Methyl Green Pyronin (MGP) stain is a differential stain used for selective staining of DNA and RNA. Methyl green binds specifically to deoxyribonucleic acid (DNA), staining nuclei green, while pyronin is specific for ribonucleic acid (RNA), staining nucleoli red. Methyl green pyronin stain has also been used to distinguish between proliferating and dedifferentiated non-proliferating cell nuclei. Similarly to assess the degradation of DNA in thyroid follicular epithelial cells, this stain has also proven to be useful.
Morphometry has been a significant advancement in delineating sequence of events responsible for cancer progression. Variations in nuclear and cellular size and shape have greater implications in the assessment of neoplastic lesions. Methyl Green Pyronin (MGP) stain has been attracting attention in the recent times as it has been used to evaluate various nuclear morphometric parameters in breast neoplasms. By using methyl green-pyronin staining, not only the inadequacies associated with AgNOR staining can be lessened but also the morphometric parameters for evaluating changes in the nucleus and nucleolus during carcinogenesis can be accomplished.
So far AgNOR staining appears to be a useful diagnostic tool in oral squamous cell carcinoma for examination of nucleolar structure and variations in nucleolar activity. On the other hand, MGP staining has been used in assessing the cancerous lesions of breast and thyroid gland and recently has been extended to oral lesions. However, no studies have been undertaken yet to evaluate and compare the morphometric parameters using these two stains within normal oral epithelium and oral squamous cell carcinoma. Similarly, very few studies have been undertaken regarding application of methyl green pyronin stain in oral pathologies.
Hence the current study has been planned to evaluate the morphometric parameters among normal oral epithelium and oral squamous cell carcinoma using methyl green pyronin staining; moreover these findings will also be compared with those of AgNOR staining. In this current scenario, methyl green pyronin staining and morphometric analysis may go hand in hand to provide a better diagnosis and early detection of oral cancer.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
Punjab
-
Lahore, Punjab, Pakistan, 54000
- Post Graduate Medical Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- ADULT
- OLDER_ADULT
- CHILD
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Specimens of normal epithelium from healthy adult individuals irrespective of age and without habits that predispose to oral cancer
- Cases of clinically and histologically confirmed primary oral squamous cell carcinoma based on WHO criteria
Exclusion Criteria:
- Subjects of oral squamous cell carcinoma with any treatment therapy other than surgical excision.
- Subjects having metastatic tumors and tumors other than in the oral cavity
- Subjects having recurrent tumors.
- Subjects of normal or control group with history of risk / predisposing factors for oral cancer.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Normal or Control group
Those subjects with normal oral epithelium will be included in this group.
|
Study Group
Those subjects with oral squamous cell carcinoma will be included in this group.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean values of diameter, area and number of nuclei and nucleoli.
Time Frame: Within one week of staining of slides
|
Morphometric parameters including diameter,area and number of nuclei and nucleoli will be determined using AgNOR and Methyl Green Pyronin staining methods.
|
Within one week of staining of slides
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Association of grading of OSCC in relation to morphometric parameters
Time Frame: Within two weeks of staining of slides
|
Chi-square test or Fisher exact test will be applied to see any statistical association of grading of OSCC in relation to morphometric parameters.
|
Within two weeks of staining of slides
|
Collaborators and Investigators
Collaborators
Investigators
- Study Director: Muhammad Eyyaz Khaleel, M.Phil, Postgraduate Medical Institute, Lahore
- Principal Investigator: Ali Raza, B.D.S, Postgraduate Medical Institute, Lahore
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- AIDER-1301-AR
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Oral Squamous Cell Carcinoma
-
National Cancer Institute (NCI)CompletedRecurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Recurrent Lip and Oral Cavity Squamous Cell Carcinoma | Recurrent Laryngeal Verrucous Carcinoma | Recurrent Oral Cavity Verrucous Carcinoma | Tongue... and other conditionsUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedHuman Papillomavirus Infection | Stage IVA Oral Cavity Squamous Cell Carcinoma | Stage IVA Oropharyngeal Squamous Cell Carcinoma | Stage IVB Oropharyngeal Squamous Cell Carcinoma | Stage IVC Oropharyngeal Squamous Cell Carcinoma | Stage I Oropharyngeal Squamous Cell Carcinoma | Stage II Oropharyngeal... and other conditionsUnited States
-
Shanghai Jiao Tong University School of MedicineCompletedStage IVA Oral Cavity Squamous Cell Carcinoma | Stage III Oral Cavity Squamous Cell CarcinomaChina
-
National Cancer Institute (NCI)TerminatedRecurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oral Cavity Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Stage IVA Oral Cavity Squamous Cell Carcinoma | Stage IVA Laryngeal Squamous Cell Carcinoma | Stage... and other conditionsCanada, United States
-
Emory UniversitySynta Pharmaceuticals Corp.TerminatedStage IVA Oral Cavity Squamous Cell Carcinoma | Stage IVA Laryngeal Squamous Cell Carcinoma | Stage IVA Oropharyngeal Squamous Cell Carcinoma | Stage I Hypopharyngeal Squamous Cell Carcinoma | Stage I Laryngeal Squamous Cell Carcinoma | Stage I Oropharyngeal Squamous Cell Carcinoma | Stage II... and other conditionsUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedRecurrent Head and Neck Squamous Cell Carcinoma | Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Caregiver | Salivary Gland Squamous Cell Carcinoma | Malignant Head and Neck Neoplasm | Recurrent Lip and Oral Cavity Squamous Cell Carcinoma | Stage... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Bristol-Myers SquibbCompletedStage IVA Oral Cavity Squamous Cell Carcinoma | Stage IV Hypopharyngeal Squamous Cell Carcinoma | Stage IVA Laryngeal Squamous Cell Carcinoma | Stage IVA Oropharyngeal Squamous Cell Carcinoma | Stage IVB Laryngeal Squamous Cell Carcinoma | Stage IVB Oropharyngeal Squamous Cell Carcinoma | Stage... and other conditionsUnited States
-
Mitchell MachtayNot yet recruitingSquamous Cell Carcinoma of the Oral Cavity or Oropharynx
-
Emory UniversityBristol-Myers Squibb; Brooklyn ImmunoTherapeutics, LLCWithdrawnStage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 | Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 | Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7 | Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma | Stage II Oral Cavity Squamous Cell...United States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)TerminatedStage I Oral Cavity Squamous Cell Carcinoma | Stage II Oral Cavity Squamous Cell CarcinomaUnited States